Colesevelam: A Review of its Use in Hypercholesterolemia

Authors: Robinson, Dean M.; Keating, Gillian M.

Source: American Journal of Cardiovascular Drugs, Volume 7, Number 6, 2007 , pp. 453-465(13)

Buy & download fulltext article:

Price: $62.95 plus tax (Refund Policy)

Abstract:

Colesevelam hydrochloride (Cholestagel^®, WelChol^®) is an orally administered, non-absorbable, polymeric, bile-acid-binding agent with a higher affinity for glycocholic acid in vitro and greater capacity for binding bile acids in vivo than other bile-acid-binding agents.

In randomized controlled trials in patients with primary hypercholesterolemia, colesevelam monotherapy reduced mean serum low-density lipoprotein-cholesterol (LDL-C) levels by 9-19%. In combination with an HMG-CoA reductase inhibitor (statin) or fenofibrate, colesevelam induced additive reductions in LDL-C 10-16% greater than those achieved by monotherapy with a statin (in patients with primary hypercholesterolemia) or fenofibrate (in patients with mixed hyperlipidemia). Colesevelam was generally well tolerated, with a relatively low incidence of gastrointestinal adverse events and a high compliance rate. Thus, colesevelam provides a useful addition to primary therapy with statins in the treatment of primary hypercholesterolemia, or fenofibrate in the treatment of mixed hyperlipidemia.

Keywords: Adis Drug Evaluations; Hyperlipidaemia

Document Type: Research article

Affiliations: 1: Wolters Kluwer Health | Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

Publication date: 2007-01-01